拉米夫定预防肝移植术后乙型肝炎病毒再感染的研究

EFFICACY OF LAMIVUDINE IN PATIENTS WITH HEPATITIS B VIRUS REINFECTION AFTER LIVER TRANSPLANTATION

为探讨拉米夫定对预防原位肝移植术后乙型肝炎病毒再感染的作用。对 7例乙型肝炎病毒感染相关终末期肝病患者行同种肝移植 ,5例于肝移植前后予拉米夫定预防乙型肝炎病毒再感染 ,2例予普通抗病毒药物阿昔洛韦治疗。结果显示 :应用拉米夫定组术后均无乙型肝炎病毒再感染 ,其中 3例随访超过 6个月 ,亦未发现有YMDD变异发生 ;2例未予拉米夫定治疗术后均发生乙型肝炎病毒再感染。

To investigate the therapeutic effect of Lamivudine on reinfection of hepatitis B virus, seven patients with terminal HBV related hepatic diseases who had received orthotopic liver transplantation, were studied. Among them, 5 patients were treated with lamivudine bcfore and after liver transplantation, and 2 patients received common antiviral treatment. No hepatitis B virus reinfection and YMDD mutations occurred in the group of patients with Lamivudine therapy. However in the group of patients receiving common antiviral therapy, both patients suffered from hepatitis B virus reinfection. Lamivudine is potentially effective in the prophylaxis of hepatitis B virus reinfection after orthotopic liver transplantation.